News | January 23, 2021
Biocon Q3 FY21 revenue up 7% at Rs. 1,879 Cr
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
The commercial production in the SML was started in November 1989.
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Novasep's viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally," said Michel Lagarde, executive vice president, Thermo Fisher.
The company is expecting tremendous growth and a better quarterly performance
Viruses evolve into new strains when there is a change to their genetic composition.
Biocon Ltd, an innovation-led global biopharmaceuticals company, has announced that the Board of its subsidiary Biocon Biologics Ltd has approved a primary equity investment of US $75 million (Rs. 555 crores) by Abu Dhabi based ADQ, one of the region’s largest holding companies.
Subscribe To Our Newsletter & Stay Updated
